{"id":657524,"date":"2023-06-28T08:02:02","date_gmt":"2023-06-28T08:02:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=657524"},"modified":"2023-06-28T08:02:02","modified_gmt":"2023-06-28T08:02:02","slug":"spinocerebellar-ataxias-market-to-grow-substantially-during-the-forecast-period-20232032-delveinsight-key-companies-seelos-therapeutics-vico-therapeutics-wave-life-sciences-biohaven-pharma","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/spinocerebellar-ataxias-market-to-grow-substantially-during-the-forecast-period-20232032-delveinsight-key-companies-seelos-therapeutics-vico-therapeutics-wave-life-sciences-biohaven-pharma_657524.html","title":{"rendered":"Spinocerebellar Ataxias Market to Grow Substantially During the Forecast Period (2023-2032) – DelveInsight | Key Companies – Seelos Therapeutics, VICO Therapeutics, Wave Life Sciences, Biohaven Pharma"},"content":{"rendered":"
\n
\"Spinocerebellar<\/a><\/div>\n
\n
Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
As per DelveInsight, the Spinocerebellar Ataxias Market is anticipated to evolve immensely in the coming years owing to the increase in the prevalent population of Spinocerebellar Ataxias patients in the 7MM, along with the expected entry of novel therapies in the market.<\/div>\n

DelveInsight’s “Spinocerebellar Ataxias Market Insights, Epidemiology, and Market Forecast 2032<\/strong>” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Spinocerebellar Ataxias market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).<\/p>\n

The report covers emerging Spinocerebellar Ataxias drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Spinocerebellar Ataxias treatment practice\/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. <\/p>\n

\"Spinocerebellar<\/p>\n

Spinocerebellar Ataxias: An Overview<\/strong><\/p>\n

Spinocerebellar Ataxia (SCA) is a genetic disorder that is progressive, degenerative, and often fatal. The clinical marker of all SCAs is a progressive loss of balance and coordination accompanied by slurred speech. The mobility and communicative skills of individuals with an SCA are restricted, which strongly impairs quality of life, and many SCAs lead to premature death. Total 48 SCAs have been identified to date.<\/p>\n

Genetically, the SCAs fall into two major groups: those caused by dynamic repeat expansion mutations (repeat expansion SCAs) and those caused by nonrepeating mutations. Further, repeat expansions are also a major cause of non-SCA inherited neurological diseases. There are at least 12 repeat expansion SCAs. Six of these diseases—SCA1, SCA2, SCA3\/Machado–Joseph disease, SCA6, SCA7, and SCA17 are caused by translated CAG repeat expansion mutations that encode stretches of pure glutamine in the respective disease proteins; these diseases are thus referred to as polyglutamine SCAs. SCA3, also known as Machado-Joseph disease, is the most common type of SCA. SCA types 9 through 36 are rare and less well characterized.<\/p>\n

Spinocerebellar Ataxias Market Key Facts<\/strong><\/p>\n